23rd Oct 2013 08:36
LONDON (Alliance News) - Deltex Medical Group PLC Wednesday said it has established a third dedicated trainer account in the US, as another hospital agreed to implement its oesophageal doppler monitoring technology, and it expects further deals in coming months, while the US regulator approved marketing of its CardioQ-ODM+ monitor in the US.
The new US hospital is one of two that agreed to adopt the doppler technology earlier in the year, it said.
The company appoints dedicated clinical trainers to support implementation of the technology. It said the trainer is now in place and the hospital will initially focus on the highest risk surgical patients, estimated at 60 per month, with a view to expanding it to all major and high risk surgery in future phases.
"This is the third dedicated trainer account we have established in the USA and comes after a period in which we have seen the strong expansion in the pipeline of US hospitals considering broad and deep adoption of oesophageal doppler monitoring," Deltex Chief Executive Ewan Phillips said in a statement.
"We expect to announce further expansion of the Deltex dedicated trainer programme in the coming months as more hospitals move from evaluation and early implementation towards wide-scale implementation of oesophageal doppler monitoring," he added.
No financial details were provided.
Deltex claims oesophageal doppler monitoring is the only therapy to measure blood flow in the central circulation in real time. Randomised, controlled trials using doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay, it says.
Separately, the company also said it would launch its CardioQ-ODM+ monitor in the US immediately after the US Food and Drug administration approved marketing of the second generation of its cardiac response monitors. Deltex had built up stocks of the product in anticipation of getting the approval, and expects the stocks to have been installed within three months and is now building a second batch. It was launched in Europe in 2012 and has become the company's best-selling monitoring product.
It said initial installations in the US will include monitors with a sales value of over GBP500,000. Similar deals have previously involved hospitals taking title to the monitors in return for providing research services and have been accounted for as sales on a barter basis with the costs carried forward and written off as the research is completed, the company said. However, this time it intends to keep ownership of the monitors and won't count installation a sales or carry forward or amortise the costs of the research.
"With a strong foothold already in the US via our first generation of monitors, we are confident in our ability to continue to grow our US hospital base and recurring probe related revenue," Phillips said.
The CardioQ-ODM has two distinct established clinical applications: firstly, to guide fluid management during surgery and secondly, to monitor cardiac output in critical care settings, the company says.
Deltex shares were up 6.6% at 16.385 pence early Wednesday.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Deltex Medical